The news in many parts of the world is that tuberculosis (TB) is reclaiming the title of the world’s most deadly infection, even as the COVID-19 pandemic continues to kill an estimated 1,450 people daily
around the world. But this is not news to African countries, which are home to one third of the people
globally who die from TB, even though they have less than one fifth of the world’s population.
It is time to treat the scourge of Tuberculosis scourge with the same urgency as we did the COVID-19 pandemic.
As countries around the world—from Kenya to Canada, South Africa to Sweden—relish the prospect of an unofficial transition of COVID-19 from pandemic to endemic and start to ease pandemic-related restrictions, many of us in the tuberculosis (TB) community find it hard to relate. In TB, we know what can happen when a pandemic becomes an accepted fact.
Global efforts to end tuberculosis (TB) are futile without dedicated investment in research into the debilitating disease that is killing 4000 people a day, Stop TB Partnership warns.
In July 1921, a French infant became the first person to receive
an experimental vaccine against tuberculosis (TB), after the mother had died from the disease. The vaccine, known as Bacille Calmette-Guérin (BCG), is the same one still used today.
New antibiotics that could treat tuberculosis may rapidly become ineffective, according to new research published by the Lancet ahead of World Tuberculosis Day.
UN member states hope to reach agreement on a diverse range of global issues in 2017, from managing the world’s oceans to banning killer robots to stopping tuberculosis, one of the world’s deadliest diseases.
Rising multi-drug resistance in patients suffering from tuberculosis, a debilitating infectious lung disease which mainly impacts the developing world, has led to a public health emergency in the southwest Pacific Island state of Papua New Guinea, according to state officials.
Hidden by the struggles to defeat Ebola, malaria and drug-resistant tuberculosis, a silent killer has been moving across the African continent, superseding infections of HIV and AIDS.
Doctors are warning of a worsening tuberculosis epidemic in Eastern Ukraine as the continuing conflict there begins to take a heavy toll on public health.
When Veronika Sintsova was diagnosed with tuberculosis in 2009, she spent six months in hospital before being discharged and allowed to continue treatment as an outpatient.
A protest in Moscow Thursday marking the U.N. International Day Against Drug Abuse and Illicit Trafficking has highlighted the ‘torture’ drug users are put through in the Russian criminal justice system.
Twenty-three-year-old Haleema (not her real name) was not the first female patient at Srinagar’s Chest Diseases Hospital in the Indian state of Kashmir to try to run away.
Argentina is one of the countries in Latin America with the highest levels of vaccination coverage. But experts are concerned about the growing campaign by vaccine critics against immunisation.
A U.S.-based civil society coalition is calling on Congress and President Barack Obama’s administration to keep spending on global health aid at current levels, warning that recent budget cuts risk a dangerous backslide in health and development gains achieved over the past three decades.
A first-time ranking of 54 top research universities in the United States and Canada has found that a miniscule percentage of funding goes to neglected diseases, despite the outsized influence that public universities play in developing medicines for illnesses often ignored by the private sector.
Patients, doctors and international aid groups are calling on donors and governments to support measures that would make treatment of drug-resistant tuberculosis more effective and accessible.
The U.S. Food and Drug Administration (FDA), the sector’s primary regulator, has given accelerated approval to a controversial new drug for use by patients suffering from forms of tuberculosis that have proven resistant to other medicines.
Innovation in the pharmaceutical industry has declined drastically in the last ten years despite the high profitability of the so-called "research-based" industry, and the availability of better and more powerful science and technological tools. Not only has productivity in terms of research fallen, but the vast majority of new molecules introduced to the market do not provide new therapeutic solutions since other treatments already exist, normally at a lower cost.
After weathering the departure of its executive director amidst a misallocation scandal earlier this year, the world's largest funder of programmes to address HIV/AIDS, tuberculosis and malaria is poised to announce a new leader Thursday.
The next several years could see either the elimination of tuberculosis in some regions or millions of otherwise preventable deaths, according to new research
released in Washington Wednesday by the World health Organisation (WHO).